Kailera Therapeutics, Inc. (KLRA)

Kailera Therapeutics, Inc. is a biopharmaceutical company focused on treatments for obesity and related metabolic conditions. Its pipeline is built on incretin-based drug candidates, including injectable and oral agents acting on GLP-1 and related hormone receptors, which it licensed from China's Jiangsu Hengrui Pharmaceuticals for development outside Greater China.

The company is advancing these candidates through clinical trials with the aim of offering weight-loss therapies that compete in the fast-growing obesity drug category. Its common stock trades on the Nasdaq, and its SEC filings provide details on its programs and trial plans.